Stocks to Buy

Whether you are a novice who just opened your first 401k or you are a seasoned investor, you have to spend countless hours researching stocks to buy. Who has that kind of time? We do. Powered by a diverse group of perspectives formed from dozens of analysts, advisors and strategists, our stories digest the day’s biggest headlines to uncover which stocks you should buy.

5 Fashion and Apparel Stocks to Buy Now

This week, five fashion and apparel stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").

3 Communications Equipment Stocks to Buy Now

The grades of three communications equipment stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.

SLB Stock: All Eyes Are On Oil Stock Giant Schlumberger

SLB stock is about to report earnings. Investors should expect some great things from the oil stock.

3 Takeover Targets You Can Bank On

With excess money floating around in equity funds looking for yield and appreciation, takeover targets abound. These 3 companies may be vulnerable in 2014

12 Commercial Banking Stocks to Buy Now

12 commercial banking stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").

9 Service Stocks to Buy Now

The grades of nine service stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.

9 Biotechnology Stocks to Buy Now

The grades of nine biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.

Should You Buy the 3D Printing Stocks Dip?

3D printing stocks are falling, and that's created better entry points for XONE stock, SSYS stock, DDD, stock and VJET stock.

4 Packaged Foods Stocks to Buy Now

The grades of four packaged foods stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.

5 Insurance Stocks to Buy Now

This week, five insurance stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").

5 Semiconductor Stocks to Buy Now

This week, five semiconductor stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").

3 Commercial Services Stocks to Buy Now

Three commercial services stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").

5 Stocks With Great Earnings Momentum — KNSY FB GIB REGI STV

This week, these five stocks have the best ratings in Earnings Momentum, one of the eight Fundamental Categories on Portfolio Grader.

5 Biotech Stocks With Big Catalysts on the Horizon

Announcements from, or about, these biotech stocks could greatly inflate their values ... or completely deflate them.

Intel Earnings: Hit or Miss, INTC Is a Buy

Analysts appear a little bearish heading into tomorrow's Intel earnings report, but long-term drivers point in favor of INTC stock.

Crude-By-Rail Is Here To Stay – 3 Best Railroad Stocks to Play It

Despite recent accidents, crude-by-rail volumes are surging ... and railroad stocks like CNI, CP and TRN are the best way to play that surge.

ICPT: Time to Catch a Rising Star With Intercept Stock?

It's never too late to invest in a long-term winner, and pharmaceutical player Intercept is on a long-term run. Here's why you should join the race...

2 Global Value Stocks to Buy

One model of profitability and value can help investors search across the globe for attractive equities. Here are two such value stocks to buy.

ACT: Actavis’s Growth Potential Anything But Generic

Pharmaceutical company Actavis is at the forefront on the production of biologic drugs, and stands to profit from them well into the future. It's a buy!